Seminars in Oncology Nursing
Volume 25, Issue 3 , Pages 183-192 , August 2009

Systemic Therapies for Squamous Cell Carcinoma of the Head and Neck

  • Sandra E. Kurtin

      Affiliations

    • Corresponding Author InformationAddress correspondence to Sandra E. Kurtin, RN, MS, AOCN®, ANP-C, Arizona Cancer Center, 3838 N. Campbell Ave, Tucson, AZ 85719

References 

  1. Clark J, Busse P, Deschler D. Head and neck cancer. In:  Chabner B,  Lynch T,  Longo D editor. Harrison's Manual of Oncology. New York, NY: McGraw Hill; 2008;593–609
  2. Davies L, Welch G. Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg. 2006;135:451–457
  3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Head and Neck Cancer. 2008 v2. Available at: http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf (accessed January 15, 2009).
  4. American Cancer Society Facts and Figures, 2009. Available at: http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf (accessed June 3, 2009).
  5. Culliney B, Birhan A, Young A, et al. Management of locally advanced or unresectable head and neck cancer. Oncology. 2008;22:1152–1172
  6. Wong S, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone. J Clin Oncol. 2006;24:2653–2658
  7. Kotwall C, Sako K, Razack MS, et al. Metastatic patterns in squamous cell cancer of the head and neck. Am J Surg. 1987;154:439–442
  8. Nishijima W, Takooda S, Tokita N, et al. Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch Otolaryngol Head Neck Surg. 1993;119:65–68
  9. Monnerate C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancer. Ann Oncol. 2002;13:995–1006
  10. Posner M, Vermorken J. Induction therapy in the modern era of combined-modality therapy for locally advanced head and neck cancer. Semin Oncol. 2008;35:221–228
  11. Colevas D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;26:2644–2652
  12. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, non metastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol. 2006;24:2612–2617
  13. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase II comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98
  14. Bourhis J, Armand C, Pignon JP, et al. for the MACH-NC Collaborative Group Update of MAHC-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy [abstract 5505]. Proc Am Soc Clin Oncol. 2004;23:488
  15. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced Head and Neck Cancer: An RTOG Analysis. J Clin Oncol. 2008;26:3582–3589
  16. Hitchcock Y, Tward J, Szabo A, et al. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head and neck cancer patients. Int J Radiat Oncol Biol Phys. 2009;73:779–788
  17. Bernier J, Coens C, Remenar , et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck: EORTC study 24971 [abstract 5522]. J Clin Oncol. 2006;24(suppl 18):285s
  18. Boner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578
  19. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 2001;49:427–433
  20. Langer M. Targeted therapy in head and neck cancer: state of the art and review of clinical applications. Cancer. 2008;112:2635–2645
  21. Haddad R, Shin D. Recent advances in head and neck cancer. N Engl J Med. 2008;359:1143–1154
  22. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. The Oncologist. 2008;13:899–910
  23. Cognetti D, Weber RS, Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008;113(suppl 7):1911–1932
  24. Laramore GE, Scoot CB, Al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinoma of the head and neck: report on Intergroup study 0034. Int J Radiat Onol Biol Phys. 1992;23:705–713
  25. Vermorken JB, Remenar E, vanHerpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Eng J Med. 2007;357:1695–1704
  26. Posner M, Hershock D, Blajman C, et al. Cisplatin and fluouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715
  27. Hui E, Sing B, Leung S, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2008;27:242–249
  28. Kalyankrishna S, Grandis J. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24:2666–2672
  29. Eisma RJ, Spiro JD, Kreutzer DL. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg. 1997;174:513–517
  30. Hawkins R, Grunberg S. Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. J Clin Oncol Nurs. 2009;13:54–64
  31. Seiwert T, Cohen E. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008;35:274–285
  32. Egloff A, Grandis J. Targeting epidermal growth factor receptor and Src pathways in head and neck cancer. Semin Oncol. 2008;35:286–297
  33. Erlich RB, Rickwood D, Coman WB, et al. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol. 2009;63:381–389
  34. Cruz JJ, Ocana A, Del Barco E, et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol. 2007;18:421–430
  35. Karvonen-Gutierrez C, Romis D, Fowler K, et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol. 2008;26:2754–2760
  36. Goldstein DP, Hynds Karell L, Christensen AJ, et al. Health-related quality of life profiles based on survivorship status for head and neck cancer patients. Head Neck. 2007;29:221–229
  37. Grignon LM, Jameson MJ, Karnell LH, et al. General health measures and long-term survival in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133:471–476
  38. Cady J. Nutritional support during radiotherapy for head and neck cancer: the role of prophylactic feeding tube placement. Clin J Oncol Nurs. 2007;11:875–880
  39. Beaver ME, Matheny KE, Roberts DB, et al. Predictors of weight loss during radiation therapy. Otolaryngol Head Neck Surg. 2001;125:645–648
  40. Elting L, Keefe D, Sonis ST, et al. Patient reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation and impact on quality of life. Cancer. 2008;113:2704–2713
  41. Lango M. Multimodal treatment for head and neck cancer. Surg Clin North Am. 2009;89:43–52
  42. Nonzee NJ, Dandade N, Markossian T, et al. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University costs of cancer care program pilot study with head and neck and nonsmall cell lung cancer patients who received care at the county hospital, a Veterans Administration hospital, or a Comprehensive Cancer Care Center. Cancer. 2008;113:1446–1452
  43. Rademaker AW, Voensh EF, Logemann JA, et al. Eating ability in head and neck cancer patients after treatment with chemoradiation: A 12-month follow-up study accounting for drop-out. Head Neck. 2003;25:1034–1041
  44. American Society of Clinical Oncology. Clinical practice guidelines. Available at: http://www.asco.org/guidelines (accessed January 18, 2009).
  45. The Multinational Association of Supportive Care in Cancer. Evidence based clinical guidelines for mucositis. Available at: http://www.mascc.org/content/125.html.
  46. Keefe D, Schubert MM, Elting S, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;105:820–831
  47. Harris D, Eilers JG, Cashavelly BJ, et al. Mucositis detailed PEP card. Oncology Nursing Society. Available at: http://www.ons.org/outcomes/volume2/mucositis/pdf/PEPCardDetailed_mucositis.pdf. (accessed January 18, 2009)
  48. Pignon JP, Maitre A, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MAHC-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69(suppl):S112–S114
  49. Hensley M, Hagerty K, Kewalramani T, et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2008;27:127–145

PII: S0749-2081(09)00060-6

doi: 10.1016/j.soncn.2009.05.001

Seminars in Oncology Nursing
Volume 25, Issue 3 , Pages 183-192 , August 2009

Article Tools